Patent · US Active

Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6

US7846674B2 · kind B2 · utility

0Cited by

5References

4Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Norbert Wild · Geretsried, DE
Viet Peter Grunert · Munich, DE
Johann Karl · Peißenberg, DE
Werner Zolg · Weilheim in Oberbayern, DE

Key dates

Filing date	Jun 21, 2006
Grant date	Dec 7, 2010
Priority date	—
Expiry date	Feb 5, 2028

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/6869
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and interleukin 6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and interleukin 6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and interleukin 6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.